Varenicline tartrate

• Catalog No.: PZ0004
• CAS Number: 375815-87-5
• M. F.: C17H19N3O6
• M. W.: 361.34926
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: (1R,12S)-5,8,14-triazatetracyclo[10.3.1.0^2,^1^1.0^4,^9]hexadeca-2,4,6,8,10-pentaene; (2R,3R)-2,3-dihydroxybutanedioic acid
• IUPAC Traditional name: L(+)-tartaric acid; chantix
• Synonyms: Champix; 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine tartrate

DATABASE IDS

• CAS Number: 375815-87-5
• MDL Number: MFCD08460603

PROPERTIES

• Empirical Formula (Hill Notation): C13H13N3 · C4H6O6
• Purity: ≥98% (HPLC)
• Apperance: white to off-white powder
• Solubility: DMSO: >5 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H400
• European Hazard Symbols: Harmful (Xn)
• European Hazard Symbols: Nature polluting (N)
• GHS Precautionary statements: P273
• RID/ADR: UN 2811 6.1/PG 1
• Risk Statements: 22-50
• Safety Statements: 22-57
• Storage Temperature: room temp
• Hazard Class: 6.1
• UN Number: 2811
• Packing Group: 1
• German water hazard class: 3

DETAILS

Description (English)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Varenicline tartrate is a partial α4β2 nicotinic receptor agonist and α7 full agonist. Varenicline competitively binds to α4β2 receptors and partially stimulates without creating a full nicotine effect, while simultaneoudly blocking the ability of nicotine to bind to the receptors. Varenicline thus blocks the ability of nicotine to activate α4β2 receptors and stimulate the central nervous mesolimbic dopamine system, believed to be the neuronal mechanism underlying reinforcement and reward experienced upon smoking.

Description (简体中文)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Varenicline tartrate is a partial α4β2 nicotinic receptor agonist and α7 full agonist. Varenicline competitively binds to α4β2 receptors and partially stimulates without creating a full nicotine effect, while simultaneoudly blocking the ability of nicotine to bind to the receptors. Varenicline thus blocks the ability of nicotine to activate α4β2 receptors and stimulate the central nervous mesolimbic dopamine system, believed to be the neuronal mechanism underlying reinforcement and reward experienced upon smoking.